Biogen Alzheimer's Drug Headed For Unfavorable Vote, Says An Analyst's Mock Panel

Biogen Alzheimer's Drug Headed For Unfavorable Vote, Says An Analyst's Mock Panel

A key Biogen Alzheimer's drug could get an unfavorable review from an FDA advisory committee, says an analyst whose mock panel voted against the drug; he lowered his BIIB stock price target.